A new tobacco-based seasonal influenza vaccine could potentially rival traditional egg-based versions, an analyst with research and consulting firm GlobalData has said.
The vaccine, which is being developed by Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508), is currently in Phase III development and aims to launch in the USA for the 2018/19 flu season.
It involves the implanting of influenza genetic material into tobacco leaves, a manufacturing process originally developed by Medicago (TSX: MDG), a Canadian biopharmaceutical company which was acquired by Mitsubishi Tanabe Pharma in 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze